168 related articles for article (PubMed ID: 34736622)
1. Chromogranin A (CgA) as a biomarker in carcinoid heart disease and NETG1/G2 neuroendocrine neoplasms of the small intestine (SI-NENs) related carcinoid syndrome.
Konsek-Komorowska SJ; Pęczkowska M; Kolasińska-Ćwikła AD; Konka M; Chrapowicki E; Ćwikła JB
Med Clin (Barc); 2022 Jul; 159(2):85-89. PubMed ID: 34736622
[TBL] [Abstract][Full Text] [Related]
2. Arterial function, biomarkers, carcinoid syndrome and carcinoid heart disease in patients with small intestinal neuroendocrine tumours.
Kostiainen I; Karppinen N; Simonen P; Rosengård-Bärlund M; Lindén R; Tarkkanen M; Gordin D; Rapola J; Schalin-Jäntti C; Matikainen N
Endocrine; 2022 Jun; 77(1):177-187. PubMed ID: 35536452
[TBL] [Abstract][Full Text] [Related]
3. Blood Chromogranin A Is Not Effective as a Biomarker for Diagnosis or Management of Bronchopulmonary Neuroendocrine Tumors/Neoplasms.
Matar S; Malczewska A; Oberg K; Bodei L; Aslanian H; Lewczuk-Myślicka A; Filosso PL; Suarez AL; Kolasińska-Ćwikła A; Roffinella M; Kos-Kudła B; Ćwikła JB; Drozdov IA; Kidd M; Modlin IM
Neuroendocrinology; 2020; 110(3-4):185-197. PubMed ID: 30995665
[TBL] [Abstract][Full Text] [Related]
4. Analysis of Patients with NET G1/G2 Neuroendocrine Tumors of the Small Intestine in the Course of Carcinoid Heart Disease-A Retrospective Study.
Konsek-Komorowska SJ; Pęczkowska M; Kolasińska-Ćwikła AD; Cichocki A; Konka M; Roszkowska-Purska K; Ćwikła JB
J Clin Med; 2023 Jan; 12(3):. PubMed ID: 36769439
[TBL] [Abstract][Full Text] [Related]
5. Chromogranin-A and N-terminal pro-brain natriuretic peptide: an excellent pair of biomarkers for diagnostics in patients with neuroendocrine tumor.
Korse CM; Taal BG; de Groot CA; Bakker RH; Bonfrer JM
J Clin Oncol; 2009 Sep; 27(26):4293-9. PubMed ID: 19667278
[TBL] [Abstract][Full Text] [Related]
6. An Assessment of Circulating Chromogranin A as a Biomarker of Bronchopulmonary Neuroendocrine Neoplasia: A Systematic Review and Meta-Analysis.
Malczewska A; Kidd M; Matar S; Kos-Kudła B; Bodei L; Oberg K; Modlin IM
Neuroendocrinology; 2020; 110(3-4):198-216. PubMed ID: 31266019
[TBL] [Abstract][Full Text] [Related]
7. Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors.
Pavel ME; Phan AT; Wolin EM; Mirakhur B; Liyanage N; Pitman Lowenthal S; Fisher GA; Vinik AI;
Oncologist; 2019 Apr; 24(4):463-474. PubMed ID: 30355775
[TBL] [Abstract][Full Text] [Related]
8. Carcinoid heart disease in patients with midgut neuroendocrine tumours.
Delhomme C; Walter T; Arangalage D; Suc G; Hentic O; Cachier A; Alkhoder S; François L; Lombard-Bohas C; Iung B; Ruszniewski P; de Mestier L
J Neuroendocrinol; 2023 Apr; 35(4):e13262. PubMed ID: 37005217
[TBL] [Abstract][Full Text] [Related]
9. Chromogranin A in diagnosing and monitoring patients with gastroenteropancreatic neuroendocrine neoplasms: a large series from a single institution.
Massironi S; Rossi RE; Casazza G; Conte D; Ciafardini C; Galeazzi M; Peracchi M
Neuroendocrinology; 2014; 100(2-3):240-9. PubMed ID: 25428270
[TBL] [Abstract][Full Text] [Related]
10. Vasostatin-1: A novel circulating biomarker for ileal and pancreatic neuroendocrine neoplasms.
Corsello A; Di Filippo L; Massironi S; Sileo F; Dolcetta Capuzzo A; Gemma M; Carlucci C; Cusini C; Colombo B; Dallatomasina A; Franchi GM; Corti A; Manzoni MF
PLoS One; 2018; 13(5):e0196858. PubMed ID: 29723285
[TBL] [Abstract][Full Text] [Related]
11. Prospective Evaluation of the NETest as a Liquid Biopsy for Gastroenteropancreatic and Bronchopulmonary Neuroendocrine Tumors: An ENETS Center of Excellence Experience.
Malczewska A; Witkowska M; Wójcik-Giertuga M; Kuśnierz K; Bocian A; Walter A; Rydel M; Robek A; Pierzchała S; Malczewska M; Leś-Zielińska I; Czyżewski D; Ziora D; Pilch-Kowalczyk J; Zajęcki W; Kos-Kudła B
Neuroendocrinology; 2021; 111(4):304-319. PubMed ID: 32335553
[TBL] [Abstract][Full Text] [Related]
12. Prospective Study of Chromogranin A as a Predictor of Progression in Patients with Pancreatic, Small-Intestinal, and Unknown Primary Neuroendocrine Tumors.
Dam G; Grønbæk H; Sorbye H; Thiis Evensen E; Paulsson B; Sundin A; Jensen C; Ebbesen D; Knigge U; Tiensuu Janson E
Neuroendocrinology; 2020; 110(3-4):217-224. PubMed ID: 31578011
[TBL] [Abstract][Full Text] [Related]
13. A score derived from routine biochemical parameters increases the diagnostic accuracy of chromogranin A in detecting patients with neuroendocrine neoplasms.
Kruljac I; Vurnek I; Maasberg S; Kust D; Blaslov K; Ladika Davidović B; Štefanović M; Demirović A; Bišćanin A; Filipović-Čugura J; Marić Brozić J; Pape UF; Vrkljan M
Endocrine; 2018 Jun; 60(3):395-406. PubMed ID: 29633144
[TBL] [Abstract][Full Text] [Related]
14. P53, Somatostatin receptor 2a and Chromogranin A immunostaining as prognostic markers in high grade gastroenteropancreatic neuroendocrine neoplasms.
Nielsen K; Binderup T; Langer SW; Kjaer A; Knigge P; Grøndahl V; Melchior L; Federspiel B; Knigge U
BMC Cancer; 2020 Jan; 20(1):27. PubMed ID: 31924180
[TBL] [Abstract][Full Text] [Related]
15. Real-world treatment patterns, resource use and costs of treating uncontrolled carcinoid syndrome and carcinoid heart disease: a retrospective Swedish study.
Lesén E; Björstad Å; Björholt I; Marlow T; Bollano E; Feuilly M; Marteau F; Welin S; Elf AK; Johanson V
Scand J Gastroenterol; 2018 Dec; 53(12):1509-1518. PubMed ID: 30449217
[TBL] [Abstract][Full Text] [Related]
16. Chromogranin A assessment in patients with neuroendocrine neoplasm of the small bowel and carcinoid syndrome treated with somatostatin analogues.
Gut P; Czarnywojtek A; Ruchała M
Adv Clin Exp Med; 2020 Nov; 29(11):1319-1324. PubMed ID: 33269818
[TBL] [Abstract][Full Text] [Related]
17. The Role of the Acute Octreotide Suppression Test in Detecting Patients with Neuroendocrine Neoplasms.
Kruljac I; Vičić I; Blaslov K; Kolak Z; Benković M; Kust D; Ladika Davidović B; Tometić G; Penavić I; Dabelić N; Vazdar L; Pavić T; Vrkljan M
Neuroendocrinology; 2018; 107(3):284-291. PubMed ID: 30114698
[TBL] [Abstract][Full Text] [Related]
18. What do we know about carcinoid heart disease in the present era?
Pęczkowska M; Konsek-Komorowska SJ; Kolasińska-Ćwikła AD; Konka M; Michałowska I; Ćwikła JB
Kardiol Pol; 2022; 80(10):990-1001. PubMed ID: 36136036
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of blood chromogranin A measurement in neuroendocrine tumours.
Seregni E; Ferrari L; Bajetta E; Martinetti A; Bombardieri E
Ann Oncol; 2001; 12 Suppl 2():S69-72. PubMed ID: 11762355
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of chromogranin A in patients with GET/NEN in the pancreas and the small intestine.
Fuksiewicz M; Kowalska M; Kolasińska-Ćwikła A; Ćwikła JB; Sawicki Ł; Roszkowska-Purska K; Drygiel J; Kotowicz B
Endocr Connect; 2018 Jun; 7(6):803-810. PubMed ID: 29724794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
